Information about Telbivudine
Telbivudine is a nucleoside analogue and antiviral inhibitor of hepatitis B virus (HBV) replication which is used alone and in combination with other agents in the therapy of the hepatitis B.
Liver safety of Telbivudine
Telbivudine does not appear to be a significant cause of drug induced liver injury, but can be associated with flares of the underlying hepatitis B either during therapy or upon withdrawal.
Mechanism of action of Telbivudine
Telbivudine (tel biv' ue deen) is the L-enantiomer of deoxythymidine (LdT) and has antiviral activity against HBV replication both in vitro and in vivo. Telbivudine is phosphorylated intracellularly to the triphosphate which inhibits the HBV polymerase and competes with deoxythymidine for incorporation into the growing viral DNA, causing inhibition of polymerase activity and DNA chain termination. Telbivudine has little or no activity against HIV replication.
FDA approval information for Telbivudine
Telbivudine was approved for use in the United States in 2006. Telbivudine is indicated for the treatment of chronic hepatitis B either alone or in combination with other agents. Telbivudine is available as 600 mg tablets under the brand name Tyzeka.
Dosage and administration for Telbivudine
The recommended adult dose is 600 mg orally once daily. Side effects of telbivudine are uncommon. Limited studies of telbivudine therapy during pregnancy suggest that it is safe for pregnant women.
Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Nucleoside Analogues (HIV)
- Protease Inhibitors (HIV)
HCV NS5A Inhibitors
HCV NS5B (Polymerase) Inhibitors
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Drugs for Herpes Virus Infections (HSV, CMV, others)
Drugs for Influenza